Skip to main content

Milestone Scientific Commences Sales of CompuFlo® Epidural Disposables within PRC Alliance Pain Relief Center in Ormond Beach, Florida

Written by Customer Service on . Posted in Public Companies.

PRC Alliance Pain Relief Center operates 8 locations across central Florida

Dr. Bakshi reports 100% success performing Epidural Steroid Injection (ESI) procedures during evaluation period

ROSELAND, N.J., April 03, 2024 (GLOBE NEWSWIRE) — Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that it has commenced sales of CompuFlo® Epidural disposables into PRC Alliance Pain Relief Center at Ormond Beach, Florida. PRC Alliance Pain Relief Centers operates 7offices and an ambulatory surgical center (ASC) located across Central Florida, with 15 providers. PRC Alliance Pain Relief Centers is a family of pain management specialists who are dedicated to relieving pain through exceptional and compassionate care.

Adoption of the technology follows a successful evaluation by Dr. Sanjay Bakshi, MD, a pain management physician and CEO of PRC Alliance Pain Relief Centers in Ormond Beach, Florida. Dr. Bakshi has been practicing for over 30 years and is triple board certified in anesthesia and pain management. Dr Bakshi completed his training in pain management at Johns Hopkins Hospital and subsequently worked there as an attending physician.

Dr. Sanjay Bakshi completed numerous cases using the CompuFlo Epidural system, in which he reported 100% clinical success. The evaluation included Epidural Steroid Injection (ESI) procedures within the lumbar, thoracic and cervical thoracic junction of the spine.

Dr. Sanjay Bakshi stated, “Following a thorough evaluation, I am highly supportive of Milestone’s CompuFlo instrument for enhancing both the speed and safety of Epidural Steroid Injection (ESI) procedures. In addition to its ease of use, the system provides both audible and visual feedback, including real-time confirmation of epidural placement, which minimizes the risk of intraoperative cerebral fluid leakage and trauma to underlying nerve roots. In turn, this enhances both the speed and safety of the procedure. I am delighted to incorporate Milestone’s CompuFlo within my clinic, which will ultimately provide a better experience for my patients.”

Arjan Haverhals, CEO and president of Milestone Scientific, stated, “We are delighted by the recent adoption of our technology within the first location of PRC Alliance Pain Relief Centers, illustrating our progress in advancing sales of our CompuFlo Epidural system within pain clinics across the U.S. The decision by physicians such as Dr. Bakshi to use CompuFlo demonstrates the clinical utility and benefit of the technology, and we believe that the increasing adoption will support our broader reimbursement strategy. Notably, we have now submitted claims for over 140 patient procedures using CPT 0777T, all of which have been successfully accepted by payor systems for processing.”

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology-focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone’s ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone’s control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone’s periodic filings with the Securities and Exchange Commission, including without limitation, Milestone’s Annual Report for the year ended December 31, 2022. The forward-looking statements in this press release are based upon management’s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact: David Waldman or Natalya Rudman
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.